Haemonetics Corp Files 8-K

TL;DR

HAE filed an 8-K, likely with financial updates. Check for details.

AI Summary

Haemonetics Corporation filed an 8-K on January 14, 2025, to report other events and financial statements. The filing does not contain specific details about the nature of these events or financial statements within the provided text.

Why It Matters

This filing indicates that Haemonetics Corporation has made a regulatory submission to the SEC, which may contain important updates for investors.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for reporting events and financial statements, with no immediate indication of negative news.

Key Players & Entities

• HAEMONETICS CORPORATION (company) — Registrant
• Massachusetts (jurisdiction) — State of incorporation
• 001-14041 (identifier) — Commission File Number
• 04-2882273 (identifier) — I.R.S. Employer Identification No.
• 125 Summer Street Boston, MA 02110 (address) — Principal executive offices
• 781 - 848-7100 (phone_number) — Registrant's telephone number
• January 14, 2025 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $67.8 m — . for total cash consideration of up to $67.8 million, including $45.3 million upfront
• $45.3 million — ation of up to $67.8 million, including $45.3 million upfront (after giving effect to certain
• $22.5 million — ertain customary adjustments) and up to $22.5 million in contingent consideration based on sa

Filing Documents

• hae-20250114.htm (8-K) — 27KB
• a8-kex991xpressrelease11425.htm (EX-99.1) — 11KB
• newlogo.jpg (GRAPHIC) — 398KB
• 0000313143-25-000006.txt ( ) — 710KB
• hae-20250114.xsd (EX-101.SCH) — 2KB
• hae-20250114_lab.xml (EX-101.LAB) — 21KB
• hae-20250114_pre.xml (EX-101.PRE) — 12KB
• hae-20250114_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. On January 13, 2025, Haemonetics Corporation (the "Company") completed the sale of its whole blood assets within its Blood Center business unit to GVS, S.p.A. for total cash consideration of up to $67.8 million, including $45.3 million upfront (after giving effect to certain customary adjustments) and up to $22.5 million in contingent consideration based on sales growth over the next three years and achievement of certain other milestones, and consistent with such other terms previously disclosed in the Company's Current Report on Form 8-K dated December 3, 2024. The Company also issued a press release on January 14, 2025 announcing the completion of the transaction, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The press release shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of such section, nor shall such information be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release issued by Haemonetics Corporation on January 14, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HAEMONETICS CORPORATION January 14, 2025 By: /s/ Christopher A. Simon Name: Christopher A. Simon Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR